136 related articles for article (PubMed ID: 30003394)
1. Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
Rediti M; Messina C
Breast Cancer Res Treat; 2018 Nov; 172(1):239-240. PubMed ID: 30003394
[No Abstract] [Full Text] [Related]
2. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
Dent R; Rugo HS
Lancet Oncol; 2021 Jan; 22(1):27-28. PubMed ID: 33387495
[No Abstract] [Full Text] [Related]
3. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli M
Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant chemotherapy in triple-negative breast cancer: is there a role for platinum?].
Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1063. PubMed ID: 25776517
[No Abstract] [Full Text] [Related]
5. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
6. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.
Poggio F; Tagliamento M; Ceppi M; Bruzzone M; Conte B; Fregatti P; Punie K; de Azambuja E; Del Mastro L; Lambertini M
Ann Oncol; 2022 Mar; 33(3):347-349. PubMed ID: 34861375
[No Abstract] [Full Text] [Related]
7. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
Tomasik B; Bieńkowski M; Jassem J
Ann Oncol; 2022 Jun; 33(6):658-659. PubMed ID: 35306157
[No Abstract] [Full Text] [Related]
8. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
Shimoi T; Noguchi E; Sudo K; Chua YJ; Yonemori K
J Clin Oncol; 2021 Nov; 39(31):3519-3521. PubMed ID: 34554822
[No Abstract] [Full Text] [Related]
9. Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Shimanuki Y; Shimomura A; Yoshimura K; Terakado H; Shimizu C
J Clin Oncol; 2021 Nov; 39(31):3521-3522. PubMed ID: 34554850
[No Abstract] [Full Text] [Related]
10. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
Jin HY; He W; Liu Q; Wang XF; Liu YF; Wei ZX
Neoplasma; 2016; 63(4):607-16. PubMed ID: 27268925
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.
Castrellon AB; Velez M; Nguyen SM; Blaya M; Barnick S; Dumais K; LeCroy N; Raez LE
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):30-33. PubMed ID: 29100977
[TBL] [Abstract][Full Text] [Related]
18. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
van Dongen MGJ; Kok M
Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
[No Abstract] [Full Text] [Related]
19. AKT1
Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
[TBL] [Abstract][Full Text] [Related]
20. Positive results for drug combo in I-SPY 2 trial.
Cancer Discov; 2014 Feb; 4(2):OF2. PubMed ID: 24501314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]